- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07227194
Machine Learning Assessment of Next-Day Migraine Likelihood
Machine Learning Assessment Of Next-Day Migraine Likelihood Collected Via The Nerivio App
Study Overview
Status
Conditions
Detailed Description
The analysis set includes patients with migraine who used Nerivio app for the reporting of migraine attacks and/or associated symptoms and/or migraine-related information.
Data collection is through the Nerivio app (Nerivio®). During app registration, patients consent to the collection of de-identified data for research purposes and provide demographic information. Participants can voluntarily report baseline characteristics such as treatment onset time relative to attack onset, headache pain, functional disability, and presence/absence of migraine-associated symptoms, as well as treatment outcomes 2-hours post-treatment. All data is stored on a HIPAA-compliant secure server.
The algorithm will be trained on user-level data. The dataset will be structured as a tabular matrix, where the columns represent risk-related features and the rows represent user-day observations. The feature set (X) serves as input variables, while the migraine occurrence label (Y) is the target outcome. The feature set (X) could be divided into four groups, according to the data source:
Demographic data - age and sex were self-reported via the app upon registration. The user's country is identified based on IP address.
Questionnaire data - features which are the patient's answers to either the daily diary questionnaire or a pre-treatment questionnaire. These include headache severity, functional disability, medication intake, aura, pain duration, and prodromal symptoms. Data on prodromal symptoms is collected via a multiple-choice question with 14 pre-defined answers.
Weather data - environmental features that are based on users' geographic location. These include barometric pressure, temperature, heat index, UV index, wind, humidity, and precipitation.
Calculated features - features that are calculated based on the aforementioned collected data. These include averages, frequencies, number of consecutive days, etc'.
Label (Y) Definition - The target variable (Y) will be defined using daily diary entries and pre-treatment questionnaires. The "next-day migraine" field served as the target outcome. A value of 1 (migraine day) will be assigned if a migraine was reported on the subsequent calendar day; a value of 0 (non-migraine day) will be assigned if no migraine was reported. Missing values were kept as null to capture potential information inherent in their non-random occurrence.
A day is classified as a migraine day (Y = 1) if both of the following conditions were met: A) Headache level was reported as mild, moderate, or severe in the diary or pre-treatment questionnaire. B) At least one additional migraine indicator was present: intake of migraine-related medication, or report of photophobia, phonophobia, nausea and/or vomiting, or aura in the diary or pre-treatment questionnaire.
The following standard ML outcome measures were used to evaluate model performance:
Precision- the percentage of migraine days correctly predicted, out of all predicted days.
Accuracy- the percentage of days correctly predicted (migraine and non-migraine), out of all the predicted days.
Sensitivity (also termed recall rate)- the percentage of migraine days correctly predicted, out of all the migraine days.
Specificity- the percentage of non-migraine days correctly predicted, out of all the non-migraine days.
Area Under the Curve (AUC)- the probability that the model ranks a migraine day higher than a non-migraine day, based on predicted risk scores (summarizing the model's ability to distinguish between migraine and non-migraine days across all classification thresholds).
F1 score- the balance between correctly predicted migraine days and avoiding wrongly-predicted migraine days, combining sensitivity and precision in one measure.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Theranica USA Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- - Nerivio users age 8 and above.
- - Filled at least 2 daily diaries/ pre-treatment reports via the Nerivio app during the same month.
Exclusion Criteria:
- NA
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Migraine patients who used the Nerivio device app
Nerivio users age 8 and above, who had filled at least 2 daily diaries or pre-treatment reports via the Nerivio app during the same month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Precision of the prediction model
Time Frame: 24 hours
|
The percentage of migraine days correctly predicted, out of all predicted days.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Specificity of the prediction model
Time Frame: 24 hours
|
The percentage of non-migraine days correctly predicted, out of all the non-migraine days
|
24 hours
|
|
Sensitivity of the prediction model
Time Frame: 24 hours
|
The percentage of migraine days correctly predicted, out of all the migraine days.
|
24 hours
|
|
Accuracy of the prediction model
Time Frame: 24 hours
|
The percentage of days correctly predicted (migraine and non-migraine), out of all the predicted days
|
24 hours
|
|
Area Under the Curve (AUC)
Time Frame: 24 hours
|
The probability that the model ranks a migraine day higher than a non-migraine day, based on predicted risk scores (summarizing the model's ability to distinguish between migraine and non-migraine days across all classification thresholds).
|
24 hours
|
|
F1 score for the prediction model
Time Frame: 24 hours
|
The balance between correctly predicted migraine days and avoiding wrongly-predicted migraine days, combining sensitivity and precision in one measure.
|
24 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RWE-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingMigraine | Migraine Headache | Migraine Without Aura | Migraine with Aura | Chronic Migraine, Headache | Episodic Migraine | Chronic Migraine Headache | Headache (Migraine) | Episodic Migraine HeadacheSpain
-
Miracle Wellness LLCNot yet recruitingMigraine | Migraine Headache | Menstrual Migraine | Menstrual Migraine (MM) Headaches | Migraine Disorder | Migraine in Adults | Migraine Disease | Migraine DisabilityUnited States
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Hinge Health, IncRecruitingMigraine | Migraine Without Aura | Migraine With AuraUnited States
-
Brigham and Women's HospitalNot yet recruitingMigraine Disorders | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States